H1 Trading update

Summary by AI BETAClose X

Renalytix plc reported unaudited revenues of $1.6 million for the first half of fiscal year 2026, with full-year revenue guidance now projected at approximately $4 million, representing a 33% year-over-year increase. The company successfully implemented three new electronic medical record integrations in the first half, with more expected in the second half, and is planning a large-scale hospital group integration involving a 1,000-patient pilot. Renalytix is also advancing a real-world evidence study to validate and expand the utility of its kidneyintelX.dkd product, which is expected to be integrated into up to five additional healthcare organizations' EMR systems. Furthermore, the relocation of laboratory operations is anticipated to deliver over $1 million in operating cost savings over five years, while the company maintained a cash balance of approximately $6 million as of December 31, 2025.

Disclaimer*

UK 100

Latest directors dealings